Cancer Stem Cell News Volume 4.15 | Apr 22 2015

Cancer Stem Cell News 4.15 April 22, 2015

Cancer Stem Cell News

     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   CSCN on Twitter

The miR-17-92 Cluster Counteracts Quiescence and Chemoresistance in a Distinct Subpopulation of Pancreatic Cancer Stem Cells
Micro-RNA (miRNA) expression analyses were performed to identify functionally defining epigenetic signatures in pancreatic cancer stem cell (CSC)-enriched sphere-derived cells and gemcitabine-resistant pancreatic CSC. [Gut] Full Article
Enter to Win a Travel Support Award to ISSCR2015!

PUBLICATIONS (Ranked by impact factor of the journal)
Lysine-Specific Demethylase 1 Promotes the Stemness and Chemoresistance of Lgr5+ Liver Cancer Initiating Cells by Suppressing Negative Regulators of β-Catenin Signaling
Researchers report that the abundant expression of leucine-rich repeat-containing G-protein-coupled receptor 5 (Lgr5) is associated with the progression of hepatocellular carcinoma (HCC). Lgr5+ HCC cells behave similarly to cancer initiating cells and are highly tumorigenic and resistant to chemotherapeutic agents. [Oncogene] Abstract

High Nitric Oxide Production, Secondary to Inducible-Nitric Oxide Synthase Expression, Is Essential for Regulation of the Tumor-Initiating Properties of Colon Cancer Stem Cells
The authors explored the contribution of nitric oxide (NO) to the development of colon cancer stem cells (CSC) features and evaluated potential strategies to treat colon cancer by modulating NO production. Their data showed an integral role for endogenous NO and inducible NO synthase activity in the biology of colon CSCs. [J Pathol] Abstract

Targeted Therapy of Glioblastoma Stem-Like Cells and Tumor Non-Stem Cells Using Cetuximab-Conjugated Iron-Oxide Nanoparticles
Treatment with cetuximab-iron-oxide nanoparticles resulted in a significant antitumor effect that was greater than with cetuximab alone due to more efficient, CD133-independent cellular targeting and uptake, epidermal growth factor receptor (EGFR) signaling alterations, EGFR internalization, and apoptosis induction in EGFR-expressing glioblastoma stem-like cells and neurospheres. [Oncotarget] Full Article

Preclinical Analysis of the Anti-Tumor and Anti-Metastatic Effects of Raf265 on Colon Cancer Cells and CD26+ Cancer Stem Cells in Colorectal Carcinoma
Cells were treated with Raf265 in combination with 5FU to demonstrate the anti-migratory and invasive effects by targeting on the CD26+ cancer stem cells and the anti-metastatic effect of the combined treatment was shown in an orthotopic colorectal carcinoma model. [Mol Cancer] Abstract | Full Article

Identification of RIP1 as a Critical Mediator of Smac Mimetic-Mediated Sensitization of Glioblastoma Cells for Drozitumab-Induced Apoptosis
Researchers report that BV6 and drozitumab synergistically induce apoptosis and reduce colony formation in several glioblastoma cell lines. Also, BV6 profoundly enhanced drozitumab-induced apoptosis in primary glioblastoma cultures and glioblastoma stem-like cells. [Cell Death Dis] Full Article

Therapeutic Targeting of CBP/β-Catenin Signaling Reduces Cancer Stem-Like Population and Synergistically Suppresses Growth of EBV-Positive Nasopharyngeal Carcinoma Cells with Cisplatin
Investigators evaluated the effect of ICG-001 on the cancer stem cell (CSC)-like population, and the combination effect of ICG-001 with cisplatin in the C666-1 Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma cells. Results showed that ICG-001 inhibited C666-1 cell growth and reduced expression of CSC-associated proteins with altered expression of epithelial-mesenchymal transition markers. [Sci Rep] Full Article

Combined Inhibition of AKT/mTOR and MDM2 Enhances Glioblastoma Multiforme Cell Apoptosis and Differentiation of Cancer Stem Cells
FC85 and ISA27 blocked proliferation and promoted the differentiation of glioma stem cells (GSCs). The simultaneous use of these compounds significantly enhanced GSC differentiation/apoptosis. [Sci Rep] Full Article

Identification of a Unique Hepatocellular Carcinoma Line, Li-7, with CD13+ Cancer Stem Cells Hierarchy and Population Change upon Its Differentiation during Culture and Effects of Sorafenib
To evaluate the CSC hierarchy, scientists investigated reconstructivity, proliferation, ALDH activity, spheroid formation, chemosensitivity and microarray analysis of the hepatocellular carcinoma cell populations sorted by FACS. [BMC Cancer] Full Article

In Vitro and In Vivo Antiproliferative Activity of Metformin on Stem-Like Cells Isolated from Spontaneous Canine Mammary Carcinomas: Translational Implications for Human Tumors
Phenotypic and functional characterization of canine mammary carcinoma (CMC)-derived stem cells was performed in vitro, by assessment of self-renewal, long-lasting proliferation, marker expression, and drug sensitivity, and in vivo, by tumorigenicity experiments. Metformin efficacy on CMC stem cell viability was analyzed both in vitro and in vivo. [BMC Cancer] Abstract

Demethoxycurcumin Was Prior to Temozolomide on Inhibiting Proliferation and Induced Apoptosis of Glioblastoma Stem Cells
Investigators showed that demethoxycurcumin (DMC) was prior to temozolomide (TMZ) on resulting in a significant increase in glioma stem cells (GSCs) apoptosis and a marked inhibition of cell growth in vitro. And combined treatment of DMC and TMZ showed more significant anti-GSC effects. [Tumor Biol] Abstract

The Novel Inhibitor BRM270 Downregulates Tumorigenesis by Suppression of NF-κB Signaling Cascade in MDR-Induced Stem Like Cancer-Initiating Cells
Researchers investigated the selective and potential efficacy of BRM270 against stem-like cancer-initiating cells via the molecular mechanisms of its anticancer effects. [Int J Oncol] Abstract

FREE Webinar: Tips & Techniques for Highly Enriched Mouse MSC Cultures as Early as Passage 0

Heterogeneity of Epidermal Growth Factor Receptor Signaling Networks in Glioblastoma
In glioblastoma (GBM) the heterogeneous expression of the epidermal growth factor receptor (EGFR) poses a substantial challenge for the effective use of EGFR-targeted therapies. Understanding the mechanisms that cause EGFR heterogeneity in GBM should provide better insights into how they, and possibly other amplified receptor tyrosine kinases, affect cellular signaling, metabolism and drug resistance. [Nat Rev Cancer] Abstract

Targeting Cancer Stem Cells Using Immunologic Approaches
Identification of specific antigens or genetic alterations in cancer stem cells (CSCs) may provide more specific targets for immunotherapy. ALDH, CD44, CD133 and HER2 have served as markers to isolate CSCs from a number of tumor types in animal models and human tumors. They might serve as useful targets for CSC immunotherapy. [Stem Cells] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Oral Milk Thistle Extract Stops Colorectal Cancer Stem Cells from Growing Tumors
Researchers showed that orally administering the chemical silibinin, purified from milk thistle, slows the ability of colorectal cancer stem cells to grow the disease. When stem cells from tumors grown in silibinin-fed conditions were re-injected into new models, the cells failed to develop equally aggressive tumors even in the absence of silibinin. [Press release from University of Colorado Cancer Center discussing research presented at the 2015 Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia] Press Release

OncoMed Presents Data on Clinical and Preclinical Anti-Cancer Stem Cell Programs at American Association for Cancer Research Annual Meeting
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, announced data from seven poster presentations. [Press release from OncoMed Pharmaceuticals, Inc. discussing research presented at the 2015 Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia] Press Release

DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083’s Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM)
DelMar Pharmaceuticals, Inc. announced promising preclinical data on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme. [Press release from DelMar Pharmaceuticals, Inc. discussing research presented at the 2015 Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia] Press Release

Cantrixil Highly Successful in Preventing Growth of Chemo-Resistant Ovarian Cancer
Novogen Ltd, its subsidiary, CanTx., Inc, and Yale University disclosed key pre-clinical data on experimental anti-cancer drug, Cantrixil, justifying the optimism in the ability of this drug candidate to significantly improve the survival outlook for patients with ovarian cancer. [Press release from Novogen Ltd discussing research presented at the 2015 Annual Meeting of the American Association for Cancer Research (AACR), Philadelphia] Press Release

From our sponsor: Want to learn more about the intestinal epithelium? Request a free wallchart from Cell.

National Cancer Institute Renews Designation for Purdue Center, Awards $8 Million
The National Cancer Institute (NCI) renewed the Purdue University Center for Cancer Research’s designation as an NCI cancer center and awarded the center $8 million in funding over the next five years. [Purdue University] Press Release

American Association for Cancer Research Recognizes 2015 Research Grantees at Annual Meeting
The American Association for Cancer Research (AACR) honored its new grantee recipients at the AACR Annual Meeting 2015. [American Association for Cancer Research] Press Release

American Association for Cancer Research Inaugurates New Leadership at 2015 Annual Meeting
The American Association for Cancer Research welcomes José Baselga, MD, PhD, as president of the organization for 2015-2016. Baselga’s research focuses on the clinical development of novel molecularly targeted agents for the treatment of cancer, particularly breast cancer, is physician-in-chief and chief medical officer at Memorial Sloan Kettering Cancer Center in New York. [American Association for Cancer Research] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Target Cancer Metabolism
May 26-28, 2015
Boston, United States

Visit our events page to see a complete list of events in the cancer stem cell community.

NEW Postdoctoral Position – Cancer Research (INSERM)

NEW Postdoctoral Fellow – Cancer & Potential Therapies (Wellcome Trust Sanger Institute)

NEW Postdoctoral Fellow – Colon Cancer (Baylor Research Institute)

Postdoctoral Research Fellow – Cell Death of Normal Tissue Stem Cells & Cancer Stem Cells (Memorial Sloan Kettering Cancer Center)

Postdoctoral Position – Cancer Biology (University of Pennsylvania)

Postdoctoral Scholar – Cancer Stem Cell Biology (Case Western Reserve University)

Postdoctoral Fellow – Breast Cancer & Stem Cell Biology (University of Cincinnati)

Postdoctoral Positions – Stem Cell and Cancer (Brigham & Women’s Hospital)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here

Learn more about Cancer Stem Cell News: Archives | Events | Contact Us